title: Report: Antibacterial activity of a peptide derived from HIV-1 MN strain gp41 envelope glycoprotein against methicillin-resistant Staphylococcus aureus.
abstract: Peptides derived from HIV-1 transmembrane proteins have been extensively studied for antimicrobial activities, and they are known as antimicrobial peptides (AMPs). These AMPs have also been reported to potently combat the drug-resistant microbes. In this study, we demonstrated that peptide #6383 originated from HIV-1 MN strain membrane-spanning domain of gp41 was active (2-log reductions) at 100βg/mL (56.5βM) against methicillin-resistant Staphylococcus aureus (MRSA) in 10% and 50% human plasma-supplemented phosphate buffered saline (PBS). The activity was further enhanced (3-log reductions) in the presence of 5% human serum albumin (HSA) alone. All bactericidal activities were achieved within 6 hours. At 100μg/mL, the peptide showed only 13% toxicity against human erythrocytes. This peptide can serve as an attractive template for a design of a novel peptide antibiotic against drug-resistant bacteria. By sequence-specific engineering or modifications, we anticipated that the bactericidal activity and the reduced toxicity against human erythrocytes will be improved.
authors.affiliation: Oncological and Radiological Sciences, Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia (USM), Bertam, Kepala Batas, Pulau Pinang, Malaysia.
authors.forename: Sin-Yeang
authors.initials: SY
authors.lastname: Teow
authors.affiliation: Oncological and Radiological Sciences, Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia (USM), Bertam, Kepala Batas, Pulau Pinang, Malaysia.
authors.forename: Syed Atif
authors.initials: SA
authors.lastname: Ali
mesh_terms: D000900:Anti-Bacterial Agents / Q000302:isolation & purification / Q000494:pharmacology* / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004912:Erythrocytes / Q000187:drug effects; D015700:HIV Envelope Protein gp41 / Q000302:isolation & purification / Q000494:pharmacology*; D015497:HIV-1 / Q000737:chemistry*; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D007700:Kinetics; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development; D050296:Microbial Viability / Q000187:drug effects; D010446:Peptide Fragments / Q000302:isolation & purification / Q000494:pharmacology* / Q000633:toxicity
chemical_list: D000900:Anti-Bacterial Agents; D015700:HIV Envelope Protein gp41; D010446:Peptide Fragments